FOR IMMEDIATE RELEASE
Tokyo, May 25, 2021
JT Terminates Exclusive License Agreement with EirGen Pharma for Calcifediol
Extended-release Capsules (JTT-762)
Japan Tobacco Inc. (JT) (TSE:2914) announced today that the company will discontinue the development of JTT-762 (RAYALDEE® Calcifediol Extended-release Capsules). JT also announced the termination of the license agreement with EirGen Pharma Ltd. (EirGen Pharma) .
JTT-762 is a novel extended-release formulation of the prohormone of calcitriol, the active form of vitamin D3, which is approved to treat secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency in the U.S. and 11 European countries. JT's decision to discontinue development of JTT-762 follows a comprehensive reconsideration of its development pipeline.
The effects of this termination of the exclusive license agreement on JT's business performance in this fiscal year will be immaterial.
About EirGen Pharma Ltd.
EirGen Pharma Ltd., established in 2005, is a world-leader in the development, registration, manufacturing and supply of high-potency pharmaceutical products to global markets. The company is headquartered Waterford, Ireland.
For more information, visit www.eirgen.com.
Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 58,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under the Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses.
For more information, visit https://www.jt.com/.
Contact for Japan Tobacco Inc.:
Dinesh Babu Thotakura, General Manager
Media and Investor Relations Division
Japan Tobacco Inc. Tokyo: +81-3-6636-2026